Asthma Treatment OTC Switches Would Face Tough Barriers
This article was originally published in The Tan Sheet
Executive Summary
Prescription asthma drugs on the brink of patent expiry could breathe new life into Rx-to-OTC switches, but not without fierce opposition from some health care providers.
You may also be interested in...
US Needs OTC Inhalers For Asthma Treatment, And FDA Should Force A Switch, Researchers Say
In addition to epinephrine inhaler indicated for emergency use FDA currently allows for nonprescription access, a “positive step forward would be to make inhaled albuterol available OTC,” say researchers in a recent JAMA article.
Merck Looks To “Exploit” Switches With Exit From J&J Joint Venture
Merck gains flexibility to pursue Rx-to-OTC switches, such as allergy drug Clarinex and cholesterol treatment Zetia by exiting its OTC joint venture with Johnson & Johnson.
Prepaid Cards Could Help OTC Switches Gain Against Rx Competitors
Medagate Corp.’s payment technology that simplifies insurance reimbursement for OTCs could help level the playing field with competing prescription products.